Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8647815 | 0.88 | BLM (0.45) | LMNABLMGRIN1GRIN2BST6GAL1 | |
| SCHEMBL3926151 | 0.88 | BLM (0.48) | LMNABLMGRIN1GRIN2BST6GAL1 | |
| SCHEMBL10935602 | 0.86 | NAAA (0.39) | BLMGRIN1GRIN2BST6GAL1NAAA | |
| SCHEMBL29202853 | 0.81 | NAAA (0.49) | LMNAGRIN1GRIN2BNAAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9585390 | 0.77 | LMNA (0.51) | LMNABLMGRIN1GRIN2BST6GAL1 | |
| SCHEMBL7370717 | 0.76 | LMNA (0.36) | LMNABLMNAAASMN1; SMN2CYP2C19 | |
| SCHEMBL8059341 | 0.76 | NAAA (0.50) | NAAASMN1; SMN2CYP2C19ALDH1A1 | |
| SCHEMBL7373342 | 0.76 | LMNA (0.38) | LMNABLMNAAACYP2C19 | |
| SCHEMBL7375190 | 0.73 | LMNA (0.34) | LMNABLMNAAA | |
| SCHEMBL3448590 | 0.73 | SLC1A1 (0.50) | BLMGRIN1GRIN2BNAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940376-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2008-07-09 | — | — | EP | claimed |
| WO-2007039869-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2007-04-12 | — | — | WO | claimed |
| EP-1940376-B1 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM SPA (IT) | 2009-03-18 | — | — | EP | disclosed |
| EP-1940376-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007039869-A3 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM SPA (IT) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007039869-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2007-04-12 | — | — | WO | disclosed |